Women's Health & Gynecology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1

This study is exploring how providing free or discounted contraceptive vouchers to mothers affects pregnancy outcomes and the well-being of their children. By making effective contraception more accessible, the research hopes to lower unintended pregnancies and support healthier child development. The study is currently recruiting many participants across several locations in the United States, which means its findings could have a broad impact on family planning and child health.

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

This Phase 2 trial is testing a combination of hormone therapies for young women with early-stage endometrial cancer who wish to preserve their fertility. If the treatment proves successful, it could offer an important option that avoids more aggressive therapies like surgery or chemotherapy. The study is recruiting participants in China and aims to provide new hope for women balancing cancer treatment with future family plans.

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

This research is investigating tirzepatide, a medication that targets both weight and tumor growth, for women with obesity and early-stage endometrial cancer or precancerous conditions. By addressing obesity alongside cancer treatment, this trial could lead to better health outcomes before surgery. The study is recruiting in the United States and involves a short course of treatment lasting about four weeks.

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

This Phase 2 trial combines new drugs, including niraparib and dostarlimab, to treat patients with recurrent or metastatic ovarian or endometrial carcinosarcoma. These cancers are often difficult to treat, and this study aims to improve response and survival rates compared to standard chemotherapy. Recruitment is underway in several European countries, focusing on patients who have already received chemotherapy treatments.

Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers

This study is testing a non-invasive method using vaginal fluid biomarkers to detect and monitor gynecological cancers early. Early detection can be critical for successful treatment, and this approach may reduce the need for invasive tests. The trial is recruiting in the United Kingdom and involves simple sample collections such as blood tests and swabs, making it easier and less stressful for patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.